IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model

Biochemical and Biophysical Research Communications

Volumn 486, Issue 2, 2017, Pages 239-244

  Liu, Hu ^a   Shen, Jun ^a   Lu, Kai ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Combinational therapy; Drug resistance; Hepatocellular carcinoma; IL 6; Immune checkpoint blockades; Immunology

Indexed keywords

CD11B ANTIGEN; CD28 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 6; PROGRAMMED DEATH 1 LIGAND 1; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CD274 PROTEIN, MOUSE; INTERLEUKIN-6, MOUSE; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD274; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER-ASSOCIATED FIBROBLASTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85015875139     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.02.128     Document Type: Article

References (19)

1. [1] Forner, A., Llovet, J.M., Bruix, J., Hepatocellular carcinoma. Lancet (London, England) 379:9822 (2012), 1245–1255, 10.1016/s0140-6736(11)61347-0 Epub 2012/02/23. PubMed PMID: 22353262.
2. [2] Altekruse, S.F., McGlynn, K.A., Reichman, M.E., Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clinical Oncol. Off. J. Am. Soc. Clin. Oncol. 27:9 (2009), 1485–1491, 10.1200/jco.2008.20.7753 Epub 2009/02/20. PubMed PMID: 19224838; PubMed Central PMCID: PMCPMC2668555.
3. [3] Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1 (2013), 1–10, 10.1016/j.immuni.2013.07.012 Epub 2013/07/31. PubMed PMID: 23890059.
4. [4] Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J. Clinical Oncol. Off. J. Am. Soc. Clin. Oncol. 33:17 (2015), 1974–1982, 10.1200/jco.2014.59.4358 Epub 2015/01/22. PubMed PMID: 25605845; PubMed Central PMCID: PMCPMC4980573.
5. [5] Kudo, M., Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. Liver cancer 6:1 (2016), 1–12, 10.1159/000449342 PubMed PMID: 27995082; PubMed Central PMCID: PMC5159737.
6. [6] Zhao, X., Subramanian, S., Intrinsic resistance of solid tumors to immune checkpoint blockade therapy. Cancer Res., 2017, 10.1158/0008-5472.CAN-16-2379 PubMed PMID: 28159861.
7. [7] Pitt, J.M., Vetizou, M., Daillere, R., Roberti, M.P., Yamazaki, T., Routy, B., et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44:6 (2016), 1255–1269, 10.1016/j.immuni.2016.06.001 PubMed PMID: 27332730.
8. [8] Ribas, A., Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5:9 (2015), 915–919, 10.1158/2159-8290.cd-15-0563 Epub 2015/08/15. PubMed PMID: 26272491; PubMed Central PMCID: PMCPMC4560619.
9. [9] Mace, T.A., Shakya, R., Pitarresi, J.R., Swanson, B., McQuinn, C.W., Loftus, S., et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut, 2016, 10.1136/gutjnl-2016-311585 Epub 2016/11/01. PubMed PMID: 27797936.
10. [10] Seluanov, A., Vaidya, A., Gorbunova, V., Establishing primary adult fibroblast cultures from rodents. J. Visualized Experiments. JoVE, 44, 2010, 10.3791/2033 Epub 2010/10/26. PubMed PMID: 20972406; PubMed Central PMCID: PMCPMC3185624.
11. [11] Wagner, E.F., Cancer: fibroblasts for all seasons. Nature 530:7588 (2016), 42–43, 10.1038/530042a Epub 2016/02/06. PubMed PMID: 26842052.
12. [12] Kalluri, R., The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16:9 (2016), 582–598, 10.1038/nrc.2016.73 Epub 2016/08/24. PubMed PMID: 27550820.
13. [13] Erez, N., Truitt, M., Olson, P., Arron, S.T., Hanahan, D., Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer cell 17:2 (2010), 135–147, 10.1016/j.ccr.2009.12.041 PubMed PMID: 20138012.
14. [14] Feig, C., Jones, J.O., Kraman, M., Wells, R.J., Deonarine, A., Chan, D.S., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. U. S. A. 110:50 (2013), 20212–20217, 10.1073/pnas.1320318110 Epub 2013/11/28. PubMed PMID: 24277834; PubMed Central PMCID: PMCPMC3864274.
15. [15] Becker, C., Fantini, M.C., Wirtz, S., Nikolaev, A., Lehr, H.A., Galle, P.R., et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell cycle (Georgetown, Tex) 4:2 (2005), 217–220 Epub 2005/01/19. PubMed PMID: 15655344.
16. [16] Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.Y., Vallabhapurapu, S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer cell 15:2 (2009), 103–113, 10.1016/j.ccr.2009.01.001 Epub 2009/02/03. PubMed PMID: 19185845; PubMed Central PMCID: PMCPMC2667107.
17. [17] Bromberg, J., Wang, T.C., Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer cell 15:2 (2009), 79–80, 10.1016/j.ccr.2009.01.009 Epub 2009/02/03. PubMed PMID: 19185839; PubMed Central PMCID: PMCPMC3684978.
18. [18] Topalian, S.L., Drake, C.G., Pardoll, D.M., Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24:2 (2012), 207–212, 10.1016/j.coi.2011.12.009 Epub 2012/01/13. PubMed PMID: 22236695; PubMed Central PMCID: PMCPMC3319479.
19. [19] Sharpe, A.H., Abbas, A.K., T-cell costimulation–biology, therapeutic potential, and challenges. N. Engl. J. Med. 355:10 (2006), 973–975, 10.1056/NEJMp068087 Epub 2006/08/16. PubMed PMID: 16908487.